Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
Bone Metastases
Brain Cancer
Business Management
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Genitourinary Cancers
Head & Neck Cancers
Hematologic Oncology
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Non-Hodgkin Lymphoma
Oncology Nursing News
Patient Resources
Sarcomas/TGCT
Special Reports in Personalized Cancer Care
Supportive Care
Online CME
Interactive Publications
SELECT A TOPIC
CURRENT VIEW
All Specialties
▲
Education ▲
Education ▼
Register
|
Login
Conference Coverage
Videos
NewsNetwork
OncLive
®
TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
More >>
OncLive TV: Haythem Y. Ali, MD
<< Back to Our Featured Experts
Dr. Ali on Adjuvant Studies With Biosimilars in Oncology
Dr. Ali on Whether Biosimilars Can Replace Biologics in Oncology
Dr. Ali on Choosing Neratinib in HER2+ Breast Cancer
Dr. Ali on the Future of Adjuvant Care for HER2+ Breast Cancer
Dr. Ali Explains Misconceptions About Biosimilars
Dr. Ali on Choosing Adjuvant Treatment for HER2+ Breast Cancer
Dr. Ali on Incorporating Biosimilars into Cancer Treatment
Oncology Specialists
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Bing Xia, MD
Joanne Xiu, PhD
OncLive News Network On Location: ASH 2019 Day 3
Trending Now
Acalabrutinib Triplet Highly Active in Frontline CLL
CAR-T Progress Continues in Non-Hodgkin Lymphoma, But Guidelines Need Updating
Dr. Smith on the Rationale Behind the Fixed Duration Trial for Ibrutinib/Venetoclax in CLL
FDA Approves Generic Everolimus Tablets
Publications
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
x
Subscribe